Last reviewed · How we verify
Caprelsa
At a glance
| Generic name | Caprelsa |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Target | AarF domain-containing protein kinase 4, Bone morphogenetic protein receptor type-1B, Chaperone activity of bc1 complex-like, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Carcinoma of thyroid
- Medullary thyroid carcinoma
Common side effects
- Diarrhea/Colitis
- Rash
- Acneiform Dermatitis
- Hypertension
- Nausea
- Headache
- Upper Respiratory Tract Infections
- Decreased Appetite
- Abdominal Pain
- Fatigue
- Dyspepsia
- Vomiting
Key clinical trials
- Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer (PHASE1)
- Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
- Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (PHASE3)
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (PHASE2)
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (PHASE2)
- Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |